Advertisement
Advertisement

VVOS

VVOS logo

Vivos Therapeutics, Inc. Common Stock

1.57
USD
Sponsored
+0.07
+4.67%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

1.53

-0.04
-2.23%

VVOS Earnings Reports

Positive Surprise Ratio

VVOS beat 8 of 19 last estimates.

42%

Next Report

Date of Next Report
Mar 30, 2026
Estimate for Q4 25 (Revenue/ EPS)
$6.42M
/
-$0.49
Implied change from Q3 25 (Revenue/ EPS)
-5.30%
/
--
Implied change from Q4 24 (Revenue/ EPS)
+73.70%
/
+75.00%

Vivos Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 19, 2025, VVOS reported earnings of -0.49 USD per share (EPS) for Q3 25, beating the estimate of -0.52 USD, resulting in a 5.81% surprise. Revenue reached 6.78 million, compared to an expected 4.91 million, with a 38.20% difference. The market reacted with a -10.17% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.49 USD, with revenue projected to reach 6.42 million USD, implying an increase of 0.00% EPS, and decrease of -5.30% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Vivos Therapeutics, Inc. Common Stock reported EPS of -$0.49, beating estimates by 5.81%, and revenue of $6.78M, 38.2% above expectations.
The stock price moved down -10.17%, changed from $2.36 before the earnings release to $2.12 the day after.
The next earning report is scheduled for Mar 30, 2026.
Based on 5 analysts, Vivos Therapeutics, Inc. Common Stock is expected to report EPS of -$0.49 and revenue of $6.42M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement